abstract |
The present invention relates to protection against malaria. More particularly, the present invention is based on the characterization of the sporozoite phase, the novel liver phase and the sporozoite P. falciparum antigen (referred to as LSA-5). This antigen is highly antigenic and the prevalence of antibodies in subjects living in endemic areas is extremely high (about 90%). The present invention relates to antigenic peptides, mixtures thereof, or conjugates comprising a portion of the polypeptide, myxotope, and LSA-5 sequences, as well as immunogenic compositions, vaccines, and kits comprising them. |